Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.

Int J MS Care

Schapiro Center for Multiple Sclerosis, Minneapolis Clinic of Neurology, Golden Valley, MN, USA (JC); Department of Neurology, University of Colorado School of Medicine, RMMSC at Anschutz, Aurora, CO, USA (TV); Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA (RJF); and Biogen, Cambridge, MA, USA (RZ, MN, SIS, VV).

Published: June 2016

Background: Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) is indicated for relapsing multiple sclerosis (MS). The objective of this study was to explore the safety and tolerability of DMF when administered with interferon beta (IFNβ) or glatiramer acetate (GA).

Methods: Patients with relapsing-remitting MS receiving established therapy with the same dose of IFNβ or GA for at least 12 months continued their prescribed therapy for 2 months (monotherapy period) and then received DMF 240 mg three times daily in addition to their prescribed MS therapy for 6 months (add-on therapy period). Safety and magnetic resonance imaging outcomes were monitored monthly.

Results: During the add-on therapy period, in the DMF+IFNβ (n = 57) and DMF+GA (n = 47) groups, the overall incidence of adverse events was 95% and 100%, respectively; the most common adverse events were flushing, diarrhea, and abdominal pain. In both groups, mean lymphocyte counts decreased but remained within normal limits, and hepatic transaminase levels increased transiently; no case met Hy's law criteria. There was no overall increased risk of infection. In both groups, gadolinium-enhancing lesion activity and new/enlarging T2 lesions decreased compared with the monotherapy period (exploratory endpoints).

Conclusions: The safety profile of DMF taken with IFNβ or GA was acceptable and consistent with the known safety profile of DMF monotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887000PMC
http://dx.doi.org/10.7224/1537-2073.2015-020DOI Listing

Publication Analysis

Top Keywords

safety tolerability
8
delayed-release dimethyl
8
dimethyl fumarate
8
administered interferon
8
interferon beta
8
glatiramer acetate
8
multiple sclerosis
8
prescribed therapy
8
therapy months
8
monotherapy period
8

Similar Publications

Growth of microbes in competitive lifestyles promotes increased ARGs in soil microbiota: insights based on genetic traits.

Microbiome

January 2025

Key Laboratory of Environment Remediation and Ecological Health, Ministry of Education, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058, China.

Background: The widespread selective pressure of antibiotics in the environment has led to the propagation of antibiotic resistance genes (ARGs). However, the mechanisms by which microbes balance population growth with the enrichment of ARGs remain poorly understood. To address this, we employed microcosm cultivation at different antibiotic (i.

View Article and Find Full Text PDF

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity.

J Transl Med

January 2025

Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, 230031, Anhui, China.

Background: Agonistic monoclonal antibodies targeting 4-1BB/CD137 have shown preclinical promise, but their clinical development has been limited by severe liver toxicity or limited efficacy. Therefore, a safe and efficient immunostimulatory molecule is urgently needed for cancer immunotherapy.

Methods: A novel anti-MSLN×4-1BB bispecific antibody (bsAb) was generated via antibody engineering, and its affinity and activity were detected via enzyme-linked immunosorbent assay (ELISA), flow cytometry, and T-cell activation and luciferase reporter assays.

View Article and Find Full Text PDF

Ion homeostasis and coordinated salt tolerance mechanisms in a barley (Hordeum vulgare L.)doubled haploid line.

BMC Plant Biol

January 2025

Shanghai Key Laboratory of Agricultural Genetics and Breeding, Key Laboratory for Safety Assessment (Environment) of Agricultural Genetically Modified Organisms of Ministry of Agriculture and Rural Affairs (Shanghai), Biotechnology Research Institute of Shanghai Academy of Agricultural Sciences, Shanghai, 201106, China.

Salinization poses a significant challenge in agriculture. Identifying salt-tolerant plant germplasm resources and understanding their mechanisms of salt tolerance are crucial for breeding new salt-tolerant plant varieties. However, one of the primary obstacles to achieving this goal in crops is the physiological complexity of the salt-tolerance trait.

View Article and Find Full Text PDF

Background: Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL.

Methods: A systematic literature search of PubMed, Cochrane, Embase, ClinicalTrials.

View Article and Find Full Text PDF

Cold stress in winter is one of the most severe abiotic stresses on plant growth and flourishing, and the selection of cold tolerant genotypes is an important strategy to ensure the safety of plant growth and development. Cyclocarya paliurus, a diclinous and versatile tree species originally in subtropical regions, has been introduced and cultivated in the warm temperate zone of China to meet the increasing market demand for its leaf yield. However, information regarding its cold tolerance remains limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!